Currently, there are 1.28B common shares owned by the public and among those 1.27B shares have been available to trade.
The company’s stock has a 5-day price change of 1.51% and 49.96% over the past three months. LRCX shares are trading -11.63% year to date (YTD), with the 12-month market performance up to 37.92% higher. It has a 12-month low price of $56.32 and touched a high of $109.34 over the same period. LRCX has an average intraday trading volume of 10.57 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 3.36%, 13.22%, and 26.10% respectively.
Institutional ownership of Lam Research Corp (NASDAQ: LRCX) shares accounts for 83.99% of the company’s 1.28B shares outstanding.
It has a market capitalization of $127.43B and a beta (3y monthly) value of 1.67. The stock’s trailing 12-month PE ratio is 27.75, while the earnings-per-share (ttm) stands at $3.59. The company has a PEG of 1.68 and a Quick Ratio of 1.64 with the debt-to-equity ratio at 0.47. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.95% over the week and 2.34% over the month.
Analysts forecast that Lam Research Corp (LRCX) will achieve an EPS of 1.2 for the current quarter, 0.98 for the next quarter and 4.03 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 1.12 while analysts give the company a high EPS estimate of 1.12. Comparatively, EPS for the current quarter was 0.81 a year ago. Earnings per share for the fiscal year are expected to increase by 32.49%, and 0.60% over the next financial year. EPS should grow at an annualized rate of 16.55% over the next five years, compared to 16.17% over the past 5-year period.
Looking at the support for the LRCX, a number of firms have released research notes about the stock. Goldman stated their Buy rating for the stock in a research note on July 10, 2025, with the firm’s price target at $115. TD Cowen coverage for the Lam Research Corp (LRCX) stock in a research note released on April 24, 2025 offered a Buy rating with a price target of $100. Oppenheimer was of a view on March 20, 2025 that the stock is Outperform, while Susquehanna gave the stock Positive rating on February 20, 2025, issuing a price target of $75- $125. Cantor Fitzgerald on their part issued Overweight rating on January 30, 2025.
